Leqembi and p-tau217: A Blood Test Offers a New Window Into Alzheimer’s
A personal look at what happened to my p-tau217 blood levels after starting Leqembi, and how new research suggests that changes in this Alzheimer’s biomarker may provide an early indication of how patients are responding to treatment.
Learn How Alzheimer’s Creeped Into My Brain
Alzheimer's doesn't begin with memory loss. It begins silently 20 to 30 years earlier as changes in beta-amyloid, toxic oligomers, inflammation, and tau gradually damage the brain. This article explains the modern science behind Alzheimer's in clear, understandable language and shows how new blood tests, biomarkers, and treatments like Leqembi are transforming diagnosis, and offering hope for the future.